 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...4647484950515253545556...208209» |
- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P3 trial, Platinum resistant: A Study of SHR-A1811 in Subjects With Ovarian Cancer (clinicaltrials.gov) - Feb 15, 2025
P3, N=300, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial: Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma (clinicaltrials.gov) - Feb 15, 2025
P2, N=29, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
Journal, Metastases: Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial. (Pubmed Central) - Feb 15, 2025
P3
PSA kinetics is a valuable prognostic factor in mHSPC treated with rezvilutamide plus ADT, and the achievement of undetectable PSA and PSA90 is associated with improved survival. These findings highlight the importance of monitoring PSA kinetics in the management of mHSPC.
- | Sulanda (surufatinib) / Hutchmed, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion: CCGLC-005: A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC (clinicaltrials.gov) - Feb 14, 2025
P2, N=23, Completed, Sponsor: Tongji Hospital
These findings highlight the importance of monitoring PSA kinetics in the management of mHSPC. Recruiting --> Completed
- || Retrospective data, Review, Journal: Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis. (Pubmed Central) - Feb 13, 2025
The combination of CDK4/6i and ET significantly improves PFS and OS compared to ET alone in both Asian and non-Asian patients with HR+/HER2-aBC. Although the magnitude of benefit appears to be independent of ethnicity, future clinical trials should devise a standardized method for stratifying patients by ethnicity to more effectively assess potential differences in treatment benefits.
- | Journal, Surgery: Safety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: a multicentre, randomised, single-blind, controlled trial. (Pubmed Central) - Feb 13, 2025
Although the magnitude of benefit appears to be independent of ethnicity, future clinical trials should devise a standardized method for stratifying patients by ethnicity to more effectively assess potential differences in treatment benefits. Remimazolam was well tolerated for the induction and maintenance of general anaesthesia in pre-school-age children and was non-inferior to propofol.
- | AiTan (rivoceranib) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Apatinib Degrades PD-L1 and Reconstitutes Colon Cancer Microenvironment via the Regulation of Myoferlin. (Pubmed Central) - Feb 13, 2025
Remimazolam was well tolerated for the induction and maintenance of general anaesthesia in pre-school-age children and was non-inferior to propofol. These findings highlight novel antitumor mechanisms of MYOF and suggest that combining apatinib with ICB therapy may improve CRC treatment outcomes, offering a promising strategy to enhance immune responses.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Halaven (eribulin mesylate) / Eisai
Journal: Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study. (Pubmed Central) - Feb 13, 2025
TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.
- ||||||| Shudi Insulin Injection (long-acting basal insulin analog) / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs (clinicaltrials.gov) - Feb 13, 2025
P3, N=513, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ. Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Nov 2024 | Trial primary completion date: Sep 2025 --> Nov 2024
- |||||||||| SHR-2004 / Jiangsu Hengrui Pharma
New P3 trial: Phase III Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (clinicaltrials.gov) - Feb 13, 2025
P3, N=1167, Not yet recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New trial: A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC (clinicaltrials.gov) - Feb 12, 2025
P=N/A, N=59, Not yet recruiting, Sponsor: Xuhua Duan
- |||| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P4 trial: HOLIDYA: The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy (clinicaltrials.gov) - Feb 12, 2025
P4, N=64, Not yet recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
New trial: T+I+XELOX: Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC (clinicaltrials.gov) - Feb 12, 2025
P=N/A, N=68, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- |||| HRS-7535 / Kailera Therapeutics
New P2 trial: Efficacy and Safety of HRS-7535 in for Heart Failure With Preserved Ejection Fraction and Obesity (clinicaltrials.gov) - Feb 11, 2025
P2, N=180, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- || HRS-7535 / Kailera Therapeutics
New P1 trial: A Clinical Study of Mass Balance of [14C]HRS-7535 (clinicaltrials.gov) - Feb 11, 2025
P1, N=6, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- | Keytruda (pembrolizumab) / Merck (MSD), plinabulin (BPI 2358) / BeyondSpring
Enrollment open: KeyPemls-005: First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC (clinicaltrials.gov) - Feb 11, 2025
P2, N=45, Recruiting, Sponsor: Xiaorong Dong
Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Nov 2024 | Trial primary completion date: Sep 2025 --> Nov 2024 Not yet recruiting --> Recruiting
- | Enrollment open, Trial completion date, Trial primary completion date: PLATFORM Study of Precision Medicine for Rare Tumors (clinicaltrials.gov) - Feb 11, 2025
P2, N=770, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Jul 2028 | Trial primary completion date: Jul 2022 --> Jul 2026
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC (clinicaltrials.gov) - Feb 11, 2025
P2, N=64, Recruiting, Sponsor: Henan Cancer Hospital
- | SHR-A2102 / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: HELEN-023: SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer (clinicaltrials.gov) - Feb 11, 2025
P2, N=52, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: HAICI: Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 10, 2025
P1/2, N=10, Recruiting, Sponsor: Zhejiang Cancer Hospital
Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Jul 2028 | Trial primary completion date: Jul 2022 --> Jul 2026 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Immunological characteristics of peripheral T cells as prognostic markers for Camrelizumab and Apatinib combination therapy in advanced squamous non-small-cell lung cancer. (Pubmed Central) - Feb 10, 2025
Not yet recruiting --> Recruiting Our findings suggest that peripheral blood circulating CD4+ CXCR3+ CD137+ cells serve as biomarkers of response to combined immunotherapy and anti-angiogenic therapy in patients with advanced squamous NSCLC, providing potential guidance for improving clinical outcomes.
- | AiTan (rivoceranib) / HLB Bio Group, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Biomarker, Journal: Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study. (Pubmed Central) - Feb 9, 2025
Baseline TP53 and DNMT3A alterations, along with persistent HER2 mutations after initial treatment, are associated with poorer prognosis. The primary mechanism of resistance to pyrotinib and apatinib in these patients may be attributed to chromatin remodeling rather than on-target alterations.
- || oxaliplatin / Generic mfg., Itari (linperlisib) / Shanghai YingLi Pharma, gemcitabine / Generic mfg.
P1/2 data, Journal: PI3K? inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial. (Pubmed Central) - Feb 9, 2025
P1b/2
The primary mechanism of resistance to pyrotinib and apatinib in these patients may be attributed to chromatin remodeling rather than on-target alterations. This study highlights the potential of linperlisib plus GEMOX as a treatment for R/R DLBCL, demonstrating a tolerable safety profile and encouraging efficacy results.
- ||| tegileridine (SHR8554) / Jiangsu Hengrui Pharma
Clinical, P2/3 data, Journal: Efficacy and safety of SHR8554 on postoperative pain in subjects with moderate to severe acute pain following orthopedic surgery: A multicenter, randomized, double-blind, dose-explored, active-controlled, phase II/III clinical trial. (Pubmed Central) - Feb 9, 2025
In conclusion, SHR8554 exhibited efficacy compared to placebo and safety comparable to morphine for patients experiencing moderate-to-severe acute pain following unilateral total knee replacement or knee ligament reconstruction surgery. TRIAL REGISTRATION: Trial Name: Study on the Efficacy and Safety of SHR8554 Injection for Postoperative Analgesia in Orthopedics: Multicenter, Randomized, Double Blind, Dose Exploration, Placebo/Positive Control, Phase II/III Clinical Trial Registered on: chinadrugtrials.org.cn Identifier: CTR20220639.
- || Biomarker, Clinical, Retrospective data, Review, Journal, PD(L)-1 Biomarker, IO biomarker: Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels. (Pubmed Central) - Feb 7, 2025
10%, Tislelizumab is expected to offer the greatest efficacy, while Camrelizumab appears to be the most effective for those with PD-L1 < 10%. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024540581.
- || Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group
P2 data, Journal: Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial. (Pubmed Central) - Feb 7, 2025
P2
Our study suggests that apatinib, sintilimab combined with carboplatin and nab-paclitaxel chemotherapy showed a promising clinical activity and manageable safety profile in early TNBC and merits further study. ClinicalTrials.gov registration: NCT04722718.
- || AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
Clinical data, Retrospective data, Review, Journal: Association of VEGFR2 Polymorphisms with Clinical Outcomes of Anti-angiogenesis Therapy in Cancer Patients: A Systematic Review and Meta-analysis. (Pubmed Central) - Feb 6, 2025
ClinicalTrials.gov registration: NCT04722718. Among VEGFR2 polymorphisms, rs2305948 (C
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Real-world evidence: HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 6, 2025
P=N/A, N=300, Recruiting, Sponsor: Sun Yat-sen University
Among VEGFR2 polymorphisms, rs2305948 (C Trial completion date: Dec 2024 --> Dec 2025
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open: Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis (clinicaltrials.gov) - Feb 6, 2025
P1/2, N=74, Recruiting, Sponsor: Fudan University
Trial completion date: Dec 2024 --> Dec 2025 Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC (clinicaltrials.gov) - Feb 6, 2025
P2, N=208, Enrolling by invitation, Sponsor: The First Affiliated Hospital of Xiamen University
- Nplate (romiplostim) / Amgen
SAFETY AND EFFICACY OF ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Firenze (Spadolini 1)) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1128;
Six patients had received oral small molecule TPO-R prior to romiplostim (avatrombopag=3, herombopag=2, eltrombopag=1), which was ineffective in all six cases. Our study shows that romiplostim alone or in combination with small molecule TPO-R agonists is effective and safe in the treatment of thrombocytopenia after allo-HSCT.
- Nplate (romiplostim) / Amgen
SAFETY AND EFFICACY OF ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Feb 5, 2025 - Abstract #EBMT2025EBMT_1127;
Six patients had received oral small molecule TPO-R prior to romiplostim (avatrombopag=3, herombopag=2, eltrombopag=1), which was ineffective in all six cases. Our study shows that romiplostim alone or in combination with small molecule TPO-R agonists is effective and safe in the treatment of thrombocytopenia after allo-HSCT.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ (clinicaltrials.gov) - Feb 5, 2025
P2, N=61, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- AiRuiKa (camrelizumab) / HLB Bio Group
Observational data, Retrospective data, Journal: Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. (Pubmed Central) - Feb 5, 2025
Second-line treatment with camrelizumab combined with chemotherapy is well-tolerated and associated with favorable oncological outcomes in patients with locally advanced, recurrent, or metastatic ESCC. Furthermore, younger patients and those who have undergone radical surgery may derive greater benefit from camrelizumab combined with chemotherapy as a second-line treatment.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Clinical protocol, Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy). (Pubmed Central) - Feb 5, 2025
P2
This trail aims to verify the efficacy and safety of the perioperative treatment regimen of anti-PD-L1 (Adebrelimab) combined with chemotherapy (capecitabine plus oxaliplatin, XELOX) for patients with resectable AEG. Considering the differences in chemotherapy regimen tolerance between Asian and Western populations, this study intends to evaluate the suitability of Adebrelimab combined with XELOX chemotherapy for the Asian population.
- | New trial: The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment (clinicaltrials.gov) - Feb 5, 2025
P=N/A, N=40, Not yet recruiting, Sponsor: Hongmei Zheng, PhD
- | NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Preclinical, Journal: In Vitro and In Vivo Visualization of Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Using Infrared Emissivity. (Pubmed Central) - Feb 4, 2025
PFHO quickly spread to form a layer over the surface of saline or meibum in vitro and was detected on the ocular surface in vivo for ?5 hours after topical administration. This supports findings that PFHO forms a long-lasting barrier to evaporation at the air-liquid interface of the tear film and thus reduces signs and symptoms of DED.
- | Journal, Checkpoint inhibition: Case report: Short-course hypofractionated radiation therapy combined with immune checkpoint inhibitors for the treatment of advanced ovarian mucinous cystadenocarcinoma. (Pubmed Central) - Feb 4, 2025
oma with FIGO stage IVB disease who was sequentially treated with paclitaxel liposomes+carboplatin, 5-Fu+CF+oxaliplatin, capecitabine+oxaliplatin, bevacizumab+FOLFOX4, S-1, and bevacizumab+oxaliplatin+raltitrexed chemotherapy...The radiotherapy target area was the metastatic lymph nodes in the right posterior part of the hepatic artery, with a radiation dose of 30 Gy/10 F. Camrelizumab, an immune checkpoint inhibitor, was administered intravenously every three weeks at a dose of 200 mg each time...Ovarian mucinous cystadenocarcinoma is a rare tumor with poor treatment efficacy and poor prognosis. Short-course hypofractionated radiation therapy combined with PD-1 inhibitors may be an effective and safe treatment strategy.
- | plinabulin (BPI 2358) / BeyondSpring
Journal: Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cells. (Pubmed Central) - Feb 3, 2025
Several MT-destabilizing drugs, including vinblastine, combretastatin A4, and plinabulin, are widely used, or are under evaluation for cancer treatment...To investigate whether differential modulation of molecular pathways might account for clinical differences, we compared gene expression and signaling pathway responses in human pulmonary microvascular endothelial cells (HPMECs), alongside the MT-stabilizing drug docetaxel and the pro-inflammatory cytokine TNF-?...This finding suggests that their distinct clinical effects are not caused by different effects on MTs, but rather by differences in drug transport, pharmacokinetics or tubulin isotype affinity. Our findings provide insights into how plinabulin might protect the bone marrow and may help medicinal chemists design MT drugs for new applications.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date: IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms (clinicaltrials.gov) - Feb 3, 2025
P=N/A, N=112, Active, not recruiting, Sponsor: University Hospital Heidelberg
Our findings provide insights into how plinabulin might protect the bone marrow and may help medicinal chemists design MT drugs for new applications. Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Nov 2025 | Trial primary completion date: Aug 2024 --> May 2025
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal: Comparison of thrombopoietin receptor agonists plus recombinant human thrombopoietin vs. recombinant human thrombopoietin alone for hematopoietic reconstruction in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation. (Pubmed Central) - Feb 2, 2025
Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Nov 2025 | Trial primary completion date: Aug 2024 --> May 2025 Although sample size and study design limit the data from this study, our findings suggest that the combination of TPO-RA (hetrombopag) and rhTPO enhances platelet recovery in comparison with rhTPO alone, without increasing adverse effects.
- | carboplatin / Generic mfg., AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Journal, PARP Biomarker, IO biomarker: Simultaneously delivery of functional gallium ions and hydrogen sulfide to endow potentiated treatment efficacy in chemo- and PARPi-resistant ovarian cancer. (Pubmed Central) - Feb 2, 2025
More importantly, the therapeutic efficacy of Ga2S3-BSA NMs and their ability to enhance the sensitivity to carboplatin and fluzoparib with negligible toxicity were further confirmed in a platinum-resistant OC animal model. Altogether, our results demonstrated a potentially safe and practical strategy by using Ga2S3-BSA NMs to combat drug resistance in platinum-resistant OC.
- || ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma, repaglinide / Generic mfg., midazolam hydrochloride / Generic mfg.
Clinical, Journal: Evaluating the Drug-Drug Interactions of SHR4640 on Repaglinide and midazolam in healthy subjects. (Pubmed Central) - Feb 1, 2025
P1
SHR4640 exerts a weak inhibitory effect on the AUC of CYP enzyme probe substrates and has minimal potential for drug-drug interactions and presents a favorable safety profile. www.clinicaltrials.gov identifier is NCT06196580 (Name: PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval).
- || Itari (linperlisib) / Shanghai YingLi Pharma
P1 data, Journal, Metastases: Phase Ib study of the oral PI3K? inhibitor linperlisib in patients with advanced solid tumors. (Pubmed Central) - Jan 31, 2025
Linperlisib showed an acceptable safety profile and preliminary clinical benefit in patients with a range of advanced solid tumors. Further studies of linperlisib safety and efficacy are warranted.
- || SHR-2554 / Treeline Biosci, Tazverik (tazemetostat) / Ipsen
Clinical, Retrospective data, Review, Journal: Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis. (Pubmed Central) - Jan 31, 2025
For SHR2554, the most prevalent grade 3 or higher TRAEs were thrombocytopenia (17%), neutropenia (8%), and anemia (7%)...EZH2 inhibitors demonstrate a manageable safety profile with a low incidence of severe TRAEs, emphasizing their potential as safe therapeutic options in cancer treatment. The low rate of severe TRAEs and the rare occurrences of treatment-related deaths support the continued clinical use and further investigation of EZH2 inhibitors.
- | Noxafil (posaconazole) / Merck (MSD)
New P2 trial: Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 31, 2025
P2, N=20, Recruiting, Sponsor: Shandong Cancer Hospital and Institute
- | AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal, Metastases: Early salvage therapy with anti-PD-1 antibody Camrelizumab in patients with advanced cervical cancer: a retrospective study. (Pubmed Central) - Jan 30, 2025
The low rate of severe TRAEs and the rare occurrences of treatment-related deaths support the continued clinical use and further investigation of EZH2 inhibitors. Camrelizumab demonstrated promising efficacy and safety as the early salvage treatment for patients with advanced cervical cancer.
- || Retrospective data, Review, Journal, PARP Biomarker: First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis. (Pubmed Central) - Jan 30, 2025
However, due to the limitations in the number and quality of included studies, these conclusions await further validation through more high-quality research. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024562981, identifier CRD42024562981.
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Trial completion, Trial completion date: Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (clinicaltrials.gov) - Jan 30, 2025
P2, N=54, Completed, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024562981, identifier CRD42024562981. Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jan 2025
- ||| AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
P3 data, Journal, Metastases: Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05). (Pubmed Central) - Jan 29, 2025
Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jan 2025 The SOXRC regimen significantly improved pCR compared with SOX alone in patients with G/GEJ adenocarcinoma with a tolerable safety profile.